C5a is one of the most potent proinflammatory mediators of the complement system. The effects of C5a are mediated through its interaction with C5a receptor (C5aR), which is a GPCR. However, targeting the C5a-C5aR axis has been extremely challenging, with one a single entity (eculizumab, an anti-C5 antibody) advancing to approval in the last 20 years. We have developed cyclic peptide C5a antagonists for both oral and i.v. administration with a goal to deliver an agent of lower cost, broader utility and higher patient satisfaction than the current standard of care. In this presentation, I’m going to highlight our efforts on design of bioactive cyclic peptides with tailored molecular properties guided with computational and NMR studies.

Design of cyclic peptide C5a antagonists guided with computational and NMR studies

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.